Tomasicchio G, Dezi A, Picciariello A, Altomare D F, Giove C, Martines G, De Fazio M, Rinaldi M
Department of Precision of Regenerative Medicine and Ionian Area, University "Aldo Moro" of Bari, Italy.
Front Surg. 2023 Mar 22;10:1145170. doi: 10.3389/fsurg.2023.1145170. eCollection 2023.
Anal fissure is one of the most common anal disease characterized by intense anal pain, and deterioration of patients quality of life. Treatment is mainly based on the topical administration of calcium antagonist or nitric oxide ointments, and in cases refractory to medical treatment patients can undergo surgery. This study aims to assess the efficacy and safety of Levorag emulgel in the treatment of acute and chronic fissures using of a validated scoring system.
A prospective observational study was carried out on patients with anal fissures between February and May 2022. The efficacy of the treatment was evaluated using the REALISE score, a new validated scoring system that rates VAS for pain, NSAID use, pain duration, bleeding, and quality of life (QoL), recorded after 10, 20 and 30 days from the beginning of treatment.
Forty patients (median age 46 years, IQR 29-57, 70% women) with acute (22, 55%) or chronic (18, 45%) anal fissures entered the study. The median anal pain score according to the VAS scale decreased significantly from 7 (IQR 4.7-8) at baseline to 1 (IQR 0-3.2, = 0.05) after 20 days. At the 30-day proctological examination, 22 patients (61%) were pain free (median VAS of 0, IQR 0-1.2, < 0.05). Pain duration after defecation measured according to the REALISE score, showed a significant decrease after 10 days, from a median value of 2 (IQR 1-4) to 1 (IQR 1-1.2) ( < 0.005). The median value of the REALISE score decreased significantly, from 15 (IQR 11-19.25) at first proctological evaluation to 4 (IQR 4-6, = 0.139) after 30 days of treatment. At day 30, complete fissure healing was achieved in 30 patients (80%). The healing rate was 82% and 78% in patients with acute and chronic anal fissures, respectively.
The use of Levorag® Emulgel may represent a safe and effective non-invasive first line treatment in patients affected by acute or chronic anal fissure.
肛裂是最常见的肛门疾病之一,其特征为肛门剧痛,会降低患者的生活质量。治疗主要基于局部应用钙拮抗剂或一氧化氮软膏,对于药物治疗无效的患者可进行手术。本研究旨在使用经过验证的评分系统评估左旋奥拉凝胶治疗急性和慢性肛裂的疗效和安全性。
2022年2月至5月对肛裂患者进行了一项前瞻性观察研究。使用REALISE评分评估治疗效果,REALISE评分是一种新的经过验证的评分系统,用于对疼痛视觉模拟评分(VAS)、非甾体抗炎药使用情况、疼痛持续时间、出血情况和生活质量(QoL)进行评分,在治疗开始后10、20和30天记录。
40例患者(中位年龄46岁,四分位间距29 - 57,70%为女性)患有急性肛裂(22例,55%)或慢性肛裂(18例,45%)进入研究。根据VAS量表,肛门疼痛中位评分从基线时的7分(四分位间距4.7 - 8)显著降至20天后的1分(四分位间距0 - 3.2,P = 0.05)。在30天的直肠检查时,22例患者(61%)无疼痛(VAS中位值为0,四分位间距0 - 1.2,P < 0.05)。根据REALISE评分测量的排便后疼痛持续时间在10天后显著降低,从中位值2分(四分位间距1 - 4)降至1分(四分位间距1 - 1.2)(P < 0.005)。REALISE评分的中位值显著降低,从首次直肠检查时的15分(四分位间距11 - 19.25)降至治疗30天后的4分(四分位间距4 - 6,P = 0.139)。在第30天,30例患者(80%)实现肛裂完全愈合。急性和慢性肛裂患者的愈合率分别为82%和78%。
左旋奥拉凝胶的使用可能是急性或慢性肛裂患者安全有效的非侵入性一线治疗方法。